NTLA Stock Forecast 2025-2026
Distance to NTLA Price Targets
NTLA Price Momentum
🤔 Considering Intellia (NTLA)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Latest NTLA Stock Price Targets & Analyst Predictions
Based on our analysis of 33 Wall Street analysts, NTLA has a bullish consensus with a median price target of $44.00 (ranging from $9.00 to $106.00). The overall analyst rating is Strong Buy (8.6/10). Currently trading at $9.14, the median forecast implies a 381.4% upside. This outlook is supported by 21 Buy, 7 Hold, and 1 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
NTLA Analyst Ratings
NTLA Price Target Range
Latest NTLA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for NTLA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 5, 2025 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Initiates | $30.00 |
| Mar 4, 2025 | Truist Securities | Joon Lee | Buy | Maintains | $50.00 |
| Feb 28, 2025 | Chardan Capital | Geulah Livshits | Buy | Maintains | $68.00 |
| Feb 28, 2025 | Wells Fargo | Yanan Zhu | Overweight | Maintains | $50.00 |
| Feb 28, 2025 | Citigroup | David Lebowitz | Neutral | Maintains | $14.00 |
| Feb 28, 2025 | Barclays | Gena Wang | Overweight | Maintains | $26.00 |
| Feb 28, 2025 | JP Morgan | Brian Cheng | Neutral | Downgrade | $13.00 |
| Jan 27, 2025 | Morgan Stanley | Terence Flynn | Equal-Weight | Downgrade | $11.00 |
| Jan 14, 2025 | Goldman Sachs | Salveen Richter | Neutral | Maintains | $12.00 |
| Jan 13, 2025 | Oppenheimer | Jay Olson | Outperform | Maintains | $40.00 |
| Jan 10, 2025 | BMO Capital | Kostas Biliouris | Outperform | Maintains | $50.00 |
| Jan 10, 2025 | Wells Fargo | Yanan Zhu | Overweight | Maintains | $60.00 |
| Nov 19, 2024 | Canaccord Genuity | Whitney Ijem | Buy | Maintains | $90.00 |
| Nov 18, 2024 | Wells Fargo | Yanan Zhu | Overweight | Maintains | $70.00 |
| Nov 18, 2024 | Chardan Capital | Geulah Livshits | Buy | Maintains | $91.00 |
| Nov 18, 2024 | Wedbush | David Nierengarten | Neutral | Reiterates | $14.00 |
| Nov 11, 2024 | Oppenheimer | Jay Olson | Outperform | Maintains | $60.00 |
| Nov 8, 2024 | Barclays | Gena Wang | Overweight | Maintains | $55.00 |
| Oct 25, 2024 | Goldman Sachs | Salveen Richter | Neutral | Maintains | $20.00 |
| Oct 25, 2024 | Citigroup | David Lebowitz | Neutral | Maintains | $19.00 |
Intellia Therapeutics Inc. (NTLA) Competitors
The following stocks are similar to Intellia based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Intellia Therapeutics Inc. (NTLA) Financial Data
Intellia Therapeutics Inc. has a market capitalization of $946.15M with a P/E ratio of -1.7x. The company generates $57.88M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is +41.3% quarter-over-quarter, while maintaining an operating margin of -1,059.9% and return on equity of -54.0%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Intellia Therapeutics Inc. (NTLA) Business Model
About Intellia Therapeutics Inc.
Develops gene-editing therapies using CRISPR technology.
Intellia Therapeutics generates revenue through the development and commercialization of gene-editing therapies targeting genetic diseases. By leveraging CRISPR/Cas9 technology, they aim to create innovative treatments that can address both monogenic disorders and cancer, thus positioning themselves strategically within the biopharmaceutical market.
Based in Cambridge, Massachusetts, Intellia is actively contributing to the evolution of medical technology and personalized medicine. Their focus on precision genomic medicines places them at the forefront of the biotechnology sector, reflecting a broader industry trend towards harnessing genetic engineering for therapeutic advancements.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
403
CEO
Dr. John M. Leonard M.D.
Country
United States
IPO Year
2016
Website
www.intelliatx.comIntellia Therapeutics Inc. (NTLA) Latest News & Analysis
A class action lawsuit has been filed against Intellia Therapeutics, Inc. (NASDAQ: NTLA) and some of its officers, as announced by law firm Bronstein, Gewirtz & Grossman, LLC.
A class action lawsuit against Intellia Therapeutics could indicate potential legal and financial risks, impacting stock price and investor confidence in the company.
A class action lawsuit has been filed against Intellia Therapeutics, Inc. (NASDAQ: NTLA). Investors may contact Pomerantz LLP for more information.
The class action lawsuit against Intellia Therapeutics could impact stock performance, investor sentiment, and potential liabilities, influencing trading decisions and valuation.
Levi & Korsinsky, LLP has filed a class action lawsuit for Intellia Therapeutics investors, addressing alleged securities fraud from July 30, 2024, to January 8, 2025.
The class action lawsuit against Intellia Therapeutics highlights potential legal risks and financial losses, which can negatively impact the company's stock price and investor confidence.
A class action lawsuit has been filed against Intellia Therapeutics (NTLA) for alleged federal securities law violations during the period from July 30, 2024, to January 8, 2025.
A class action lawsuit against Intellia Therapeutics may lead to financial liabilities and affect stock performance, signaling potential risks for current and prospective investors.
Investors in Intellia Therapeutics, Inc. (NASDAQ:NTLA) who have incurred losses may explore options for recovery under federal securities laws. More information is available through a provided link.
News of a potential lawsuit against Intellia Therapeutics could signal financial instability or legal risks, impacting stock performance and investor confidence.
A class action lawsuit has been filed against Intellia Therapeutics (NASDAQ: NTLA) for alleged federal securities law violations, covering investors who bought shares from July 30, 2024, to January 8, 2025.
The class action lawsuit against Intellia Therapeutics indicates potential legal and financial risks, which could negatively impact the company's stock performance and investor confidence.
Frequently Asked Questions About NTLA Stock
What is Intellia Therapeutics Inc.'s (NTLA) stock forecast for 2025?
Based on our analysis of 33 Wall Street analysts, Intellia Therapeutics Inc. (NTLA) has a median price target of $44.00. The highest price target is $106.00 and the lowest is $9.00.
Is NTLA stock a good investment in 2025?
According to current analyst ratings, NTLA has 21 Buy ratings, 7 Hold ratings, and 1 Sell ratings. The stock is currently trading at $9.14. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for NTLA stock?
Wall Street analysts predict NTLA stock could reach $44.00 in the next 12 months. This represents a 381.4% increase from the current price of $9.14. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Intellia Therapeutics Inc.'s business model?
Intellia Therapeutics generates revenue through the development and commercialization of gene-editing therapies targeting genetic diseases. By leveraging CRISPR/Cas9 technology, they aim to create innovative treatments that can address both monogenic disorders and cancer, thus positioning themselves strategically within the biopharmaceutical market.
What is the highest forecasted price for NTLA Intellia Therapeutics Inc.?
Price targets from Wall Street analysts for NTLA are not currently available. The stock is trading at $9.14.
What is the lowest forecasted price for NTLA Intellia Therapeutics Inc.?
The lowest price target for NTLA is $9.00 from at , which represents a -1.5% decrease from the current price of $9.14.
What is the overall NTLA consensus from analysts for Intellia Therapeutics Inc.?
The overall analyst consensus for NTLA is bullish. Out of 33 Wall Street analysts, 21 rate it as Buy, 7 as Hold, and 1 as Sell, with a median price target of $44.00.
How accurate are NTLA stock price projections?
Stock price projections, including those for Intellia Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
